Insulet Corporation  (PODD)
Other Ticker:  

  Insulet Corporation Outlook

On May 10 2024 the Insulet Corporation provided following guidance

higher than expected demand for the Omnipod insulin pump system. Gross margin for the first quarter of 2024 was 65.9%, compared to 66.4% in the prior year, primarily driven by increased investments in manufacturing and distribution capacity to support future growth.

Operating income for the first quarter of 2024 was $82.5 million, or 18.7% of revenue, compared to $71.5 million, or 19.9% of revenue in the prior year. Net income for the first quarter of 2024 was $60.2 million, or $0.94 per share, compared to $53.8 million, or $0.84 per share in the prior year.

We are very pleased with our strong start to 2024, driven by robust demand for our Omnipod insulin pump system, said Shacey Petrovic, President and Chief Executive Officer. Our focus on expanding access to insulin pump therapy and providing innovative solutions for people with diabetes is resonating with customers and driving our growth.

Insulet Corporation continues to expect full year 2024 revenue to be in the range of $1.74 billion to $1.78 billion, representing growth of 16% to 19% in constant currency. The Company also reiterated its full year 2024 operating income margin guidance of approximately 17% to 19%.

In conclusion, Insulet Corporation's strong first quarter performance and positive outlook for the full year 2024 reflect the Company's continued commitment to innovation and growth in the diabetes management market.

On February 22 2024 the Insulet Corporation provided following guidance

Insulet Corporation, a leading provider of tubeless insulin pump technology under the Omnipod brand, has reported a significant increase in revenue for the full year 2023. The company saw a 30% increase in revenue, amounting to $1.7 billion, compared to $1.3 billion in the previous year. When adjusted for constant currency, the revenue growth was 29.6%, exceeding the company's guidance range of 26% to 27%.

In the fourth quarter of 2023, Insulet experienced a year-over-year revenue increase of 38%, or 37% in constant currency. These strong financial results demonstrate the company's continued growth and success in the market. With its innovative products and commitment to providing quality healthcare solutions for individuals with diabetes, Insulet is well-positioned for continued success in the future.


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com